Iqwig
German pricing rules hit Eisai’s Halaven
Richard Staines
cancer, Eisai, Iqwig, metastatic liposarcoma
0 Comment
Drug has “no additional benefit” in metastatic liposarcoma, says IQWiG.
Articles/ Brexit/ Clinical/ Pharma Market Access/ R&D/ UK & Europe/ US/ Views and analysis
The biggest pharma stories of 2016 so far
Linda Banks
Adaptive Pathways, Allergan, AZ, Brexit, Duchenne, Entresto, Gliead, GSK, Hep C, Iqwig, market access, Novartis, Pfizer, pharma, regulators, Theranos
0 Comment
The top 10 pharma milestones of the year to date.
German watchdog criticises EMA adaptive pathways approval
Andrew McConaghie
Adaptive Pathways, ema, Iqwig
0 Comment
Cost effectiveness agency critical of real world evidence plans